Trial Profile
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Anacetrapib (Primary) ; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 26 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Dec 2013 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea; KCT0000937)